What You Should Know
- Rad AI has appointed David Leonard as Chief Operating Officer (COO) and Elizabeth Bergey, MD, as the company’s first Chief Clinical Officer (CCO).
- Leonard, previously Head of Operations, Strategy, and Investor Relations, will focus on scaling internal infrastructure and enhancing go-to-market strategies for AI-enabled reporting.
- Dr. Bergey, a board-certified radiologist and former CEO of Quantum Radiology, transitions from Chief Medical Innovation Officer to lead clinical strategy and medical affairs.
The radiology sector is currently facing a “perfect storm” of rising imaging volumes and a shrinking workforce, leading to unprecedented levels of physician burnout. Rad AI, a leader in generative AI for medical imaging, is moving to address these systemic pressures by reinforcing its executive leadership. The appointments of David Leonard as COO and Dr. Elizabeth Bergey as CCO signal a strategic shift toward enterprise-scale operations supported by deep clinical governance.
By formalizing these roles, Rad AI is positioning itself to move beyond being a provider of innovative tools to becoming a foundational layer of clinical infrastructure. The company’s focus remains on ensuring that as AI adoption accelerates, the technology remains grounded in the practical, daily realities of the radiologist’s workflow.
Scaling Infrastructure for Global Demand
David Leonard’s transition to COO marks a new phase in Rad AI’s business lifecycle. With decades of experience in high-growth technology, Leonard is tasked with evolving the company’s internal operations to support large-scale deployments across global health systems. His mandate includes ensuring that new partnerships translate into long-term enterprise success, providing the operational discipline necessary to deliver AI solutions that are both reliable and deeply integrated into the healthcare ecosystem.
This operational scaling is critical as health systems increasingly look for long-term AI partners. In 2025, KLAS research identified Rad AI as one of the top five companies health system leaders consider for AI partnerships. Leonard’s leadership will be central to maintaining this momentum while navigating the complexities of multi-site, multi-national implementations.
Integrating Clinical Strategy with Medical Affairs
The appointment of Dr. Elizabeth Bergey as the company’s first CCO underscores the importance of “Radiologist-Led” innovation. Having served as the CEO of one of the largest radiology groups in the Southeast, Dr. Bergey brings an unmatched understanding of the financial and administrative burdens facing modern practices. Her role as CCO will involve bridging the gap between cutting-edge generative AI and the clinical standards required for patient care.
Under Dr. Bergey’s guidance, Rad AI’s clinical strategy will focus on refining solutions like Rad AI Continuity, which automates the follow-up process for incidental findings that could indicate early-stage cancers. By aligning the product roadmap with medical affairs, the company ensures that its AI does more than just generate reports—it actively closes care gaps and improves longitudinal patient outcomes.
